GFP/Luc Reporter Cell Line - NCI-H2087

NCI-H2087 is a human non-small cell lung cancer (NSCLC) cell line derived from a lung adenocarcinoma and is widely used in studies of lung cancer biology, tumor progression, and therapeutic response. The cell line exhibits epithelial characteristics and serves as a valuable model for investigating molecular pathways involved in tumor growth, invasion, and resistance to anti-cancer treatments. NCI-H2087 has been employed in a variety of preclinical studies focused on oncogenic signaling, targeted therapy development, and biomarker discovery in lung cancer. The GFP/Luc Reporter Cell Line - NCI-H2087 is established through stable integration of green fluorescent protein (GFP) and firefly luciferase (Luc) reporter genes into the parental NCI-H2087 cells. This dual-reporter system enables both fluorescence-based cellular visualization and highly sensitive bioluminescence detection while preserving the fundamental biological characteristics and growth behavior of the original cell line.

The NCI-H2087-GFP/Luc reporter cell line is broadly utilized in lung cancer research for real-time assessment of tumor growth, metastatic dissemination, and therapeutic efficacy. Luciferase expression allows non-invasive longitudinal monitoring of tumor burden in xenograft models through bioluminescence imaging, facilitating dynamic evaluation of disease progression and treatment response in living animals. GFP expression provides a convenient tool for visualizing cell proliferation, migration, invasion, and tissue localization in both in vitro and ex vivo studies. This model is particularly valuable for screening novel anti-cancer compounds, evaluating targeted therapies, and investigating mechanisms of drug resistance in non-small cell lung cancer. In addition, the dual-reporter platform supports studies of tumor microenvironment interactions, oncogenic signaling pathways, and metastatic processes. With stable reporter gene expression and reproducible imaging performance, the NCI-H2087-GFP/Luc cell line offers a robust experimental platform for preclinical drug development and translational research in lung adenocarcinoma and other NSCLC-related applications.